Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

tt R. Plotkin, M.D., Ph.D., director of the Neurofibromatosis Clinic at the Pappas Center for Neuro-Oncology in the Massachusetts General Hospital Cancer Center. "If shown to be efficacious, we believe that its oral administration and generally well-tolerated profile could make PTC299 an especially appealing treatment approach for NF2 patients with growing vestibular schwannomas."

The new PTC299 clinical study is an open-label Phase 2 trial that will evaluate the efficacy, safety, and pharmacodynamics of PTC299 in up to 25 patients with NF2 for up to 48 weeks. The primary objective of the study is to assess how PTC299 affects tumor volume and changes in hearing and word recognition among patients with NF2. The trial will also assess the effects of PTC299 on tumor blood flow and VEGF-related proteins. The study will be conducted at the Massachusetts General Hospital in Boston, Massachusetts.

"We are excited to rapidly advance the clinical development of PTC299 in NF2," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics. "We are hopeful that the novel mechanism of PTC299 will address unmet medical need for patients with NF2, building upon ongoing evaluations of the drug in patients with metastatic breast cancer, Kaposi's sarcoma, and other solid tumors."

In previous Phase 1 clinical studies, PTC299 was generally well tolerated by healthy volunteers who received single or multiple doses, with no serious, dose-limiting or definitively drug-related adverse events reported. All clinical adverse events observed were mild or moderate in severity, did not require intervention, and were not clearly related to PTC299. In addition, adverse events such as bleeding, hypertension and proteinuria were not observed.

The Phase 2 clinical trial of PTC299 is supported by a grant from the U.S. Department of Defense Neurofibromatosis Research Program.

About PTC299
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  AnaptysBio, Inc., a leader in the ... announced the advancement of its first-in-class anti-interleukin-36 ... The Company,s anti-IL-36R therapeutic antibody, called ANB019, ... psoriasis (GPP), an orphan systemic inflammatory disease ... owned within AnaptysBio,s proprietary antibody pipeline and ...
(Date:4/16/2015)... 16, 2015 Avelas Biosciences, an in ... surgeries, announced today that it has initiated a Phase ... in women with primary, non-recurrent breast cancer undergoing surgery. ... the addition of Steven Chen , M.D., as ... label, dose escalation study will enroll up to 39 ...
(Date:4/16/2015)... , Switzerland , ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ , ... drugs that target unmet medical needs as ... preclinical data on the investigational compounds Debio 1143 ... will be presented at the 2015 Annual ...
(Date:4/16/2015)... NJ (PRWEB) April 16, 2015 ... Dr. Joseph V. Gulfo to become the Executive ... Entrepreneurship. Simultaneously, FDU announced the kick-off of the ... program spearheaded by Dr. Gulfo, under the Rothman ... College of Business) and in collaboration with FDU’s ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... Looking to raise more venture capital for clinical trials, ... at the annual InvestMidwest venture capital forum next ... at the 2006 forum, would like to raise an additional ... trials that are set to begin in early 2008. ...
... the key skills for today's success are flexibility, adaptability, ... in order to compete in the global marketplace. This ... misperception that there is a shortage of highly skilled, ... there are many qualified, highly skilled, technical people here, ...
... ago, I had no idea that I would continue with it ... to share with other members of the Midwest life-science community information ... just overall awareness about life science in the Midwest. , ... I couldn't afford the kind of market research we used to ...
Cached Biology Technology:ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3Getting beyond the vortex of corporate mediocrity 2Getting beyond the vortex of corporate mediocrity 3Getting beyond the vortex of corporate mediocrity 4A Midwest life-science odyssey comes full circle 2A Midwest life-science odyssey comes full circle 3A Midwest life-science odyssey comes full circle 4A Midwest life-science odyssey comes full circle 5A Midwest life-science odyssey comes full circle 6A Midwest life-science odyssey comes full circle 7A Midwest life-science odyssey comes full circle 8
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... criminalistics from Brazil, China, Arab Emirates, Spain, USA, Philippines, ... United Nations (UNODC) will meet in Granada next October ... Prokids Scientific Group Meeting. The meeting will ... worldwide database with genetic information of human trafficking victims ...
... , HONG KONG, Oct. 15 /PRNewswire-Asia/ ... software and hardware,products, announces that its Windows Biometric Framework (WBF) ... for both 32 bit and,64 bit Windows 7, a new ... driver is digitally signed by Microsoft and it may be ...
... faculty from more than 40 academic institutions in North ... first annual Undergraduate Research Conference at the Interface of ... Mathematical and Biological Synthesis (NIMBioS). Undergraduates in biology, ... and present posters on topics ranging from modeling diseases ...
Cached Biology News:DNA against traffic in human beings 2Futronic Windows 7 Biometric Framework Driver is Signed by Microsoft 2
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
ZBP-89 (S-15)...
... ligase (AMP forming), Acetate thiokinase ... Physical form: Lyophilized powder containing ... glutathione Preparation Unit Definition: One ... coenzyme A from acetate, ATP and coenzyme ...
... is specifically designed to target and display ... cerevisiae. Displayed proteins can be analyzed for ... putative ligands. pYD1 uses the a-agglutinin yeast ... Aga1 and Aga2 to display recombinant protein ...
Biology Products: